Insights
Search Results
Client Highlights
3.04.25
Wilson Sonsini Advises WuXi AppTec on Sale of U.S. Medical Device Testing Operations to NAMSA
On March 3, 2025, WuXi AppTec announced that it had completed the sale of its U.S. medical device testing operations to NAMSA. Wilson Sonsini is pleased to have represented WuXi AppTec throughout this transaction.
Client Highlights
1.21.25
Wilson Sonsini Advises WuXi AppTec on Sale of Its U.S. Medical Device Testing Operations to NAMSA
On January 17, 2025, WuXi AppTec, a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that it has entered into a definitive agreement to sell its U.S. medical device testing operations to NAMSA, a Toledo, Ohio-based MedTech testing, clinical, and regulatory consulting firm. Under the agreement, NAMSA will acquire WuXi AppTec’s medical device testing facilities in Minnesota and Georgia. Wilson Sonsini Goodrich & Rosati advised WuXi AppTec on the transaction.
Client Highlights
3.21.24
Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio
On March 21, 2024, LENZ Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, announced the completion of its previously announced merger with Graphite Bio, Inc. The new combined company will operate under the name LENZ Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction.
Client Highlights
11.15.23
Wilson Sonsini Represents LENZ Therapeutics in Merger with Graphite Bio
On November 15, 2023, LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over the age of 45. The combined company is expected to trade on Nasdaq under the ticker symbol “LENZ.” Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction.
Client Highlights
9.07.23
Wilson Sonsini Advises Idorsia on Reacquisition of Global Rights to Aprocitentan
On September 6, 2023, Idorsia Ltd announced that it has entered into an agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the return of worldwide rights for aprocitentan to Idorsia. Aprocitentan is an oral, dual endothelin receptor antagonist currently under review with health authorities for the treatment of patients with resistant hypertension. In return, Idorsia is committed to pay up to 306 million Swiss francs, or about $343 million, subject to marketing application approval by the U.S. FDA and Europe’s EMA. Wilson Sonsini Goodrich & Rosati represented Idorsia in the transaction.
Client Highlights
4.12.23
Wilson Sonsini Advises Aspect Biosystems on $2.7 Billion Collaboration with Novo Nordisk
On April 12, 2023, Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, and leading global healthcare company Novo Nordisk A/S announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. Wilson Sonsini Goodrich & Rosati advised Aspect Biosystems on the transaction.